Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Medivation ( MDVN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.1%. By the end of trading, Medivation fell $0.64 (-1.1%) to $57.23 on average volume. Throughout the day, 1,550,922 shares of Medivation exchanged hands as compared to its average daily volume of 1,061,400 shares. The stock ranged in price between $55.37-$58.20 after having opened the day at $55.68 as compared to the previous trading day's close of $57.87. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 38.6%, Reliv' International ( RELV), down 16.7%, Halozyme Therapeutics ( HALO), down 14.0% and Senesco Technologies ( SNTI), down 12.0%.

Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. Medivation has a market cap of $4.3 billion and is part of the health care sector. Shares are up 11.1% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Medivation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Medivation as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk.

On the positive front, Zalicus ( ZLCS), up 30.9%, Biocryst Pharmaceuticals ( BCRX), up 21.1%, Anika Therapeutics ( ANIK), up 20.9% and GW Pharmaceuticals PLC ADR ( GWPH), up 16.7% , were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

AMD Rises Above the Competition; Loan Losses Mount for Big Banks -- ICYMI

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

McKesson Internal Review Clears Senior Management of Wrongdoing on Opioids

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2